SteelPeak Wealth LLC purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 16,000 shares of the company’s stock, valued at approximately $448,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of HRMY. Allspring Global Investments Holdings LLC grew its position in Harmony Biosciences by 750.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 176,219 shares of the company’s stock valued at $4,927,000 after acquiring an additional 155,494 shares in the last quarter. Illinois Municipal Retirement Fund lifted its position in shares of Harmony Biosciences by 3.8% during the first quarter. Illinois Municipal Retirement Fund now owns 20,020 shares of the company’s stock worth $561,000 after purchasing an additional 727 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Harmony Biosciences in the first quarter valued at $1,030,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Harmony Biosciences by 31.0% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 9,115 shares of the company’s stock valued at $255,000 after purchasing an additional 2,155 shares during the period. Finally, Illumine Investment Management LLC grew its holdings in Harmony Biosciences by 4.4% during the 1st quarter. Illumine Investment Management LLC now owns 24,277 shares of the company’s stock valued at $680,000 after purchasing an additional 1,032 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.
Harmony Biosciences Stock Up 0.7%
HRMY stock opened at $33.77 on Friday. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The firm has a 50 day simple moving average of $33.46 and a 200-day simple moving average of $32.71. The company has a market capitalization of $1.96 billion, a P/E ratio of 13.62, a PEG ratio of 0.32 and a beta of 0.94. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.
Analyst Ratings Changes
Several research firms recently issued reports on HRMY. Weiss Ratings raised shares of Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. Truist Financial upped their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised their target price on Harmony Biosciences from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Tuesday, June 30th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.50.
Read Our Latest Stock Analysis on HRMY
Harmony Biosciences Profile
Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.
The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.
Featured Articles
- Five stocks we like better than Harmony Biosciences
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
